Compare GE Vernova Inc (GEV) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Vernova Inc vs Gilead Sciences, Inc. — how do they compare? GE Vernova Inc trades at $1,007.89 (market cap $266.16B), while Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B). The key difference: GE Vernova Inc is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold GE Vernova Inc for 36 Days and Gilead Sciences, Inc. for 111 Days on average.
| GEV | GILD | |
|---|---|---|
Market Cap | $266.16B | $182.40B |
Volume | 2,324,165 | 4,469,821 |
Sector | Industrials | Health |
52-Week High | $1.17K | $155.80 |
52-Week Low | $547.96 | $116.74 |
Typical Hold Time | 36 Days | 111 Days |
Enterprise Value | $255.83B | $205.46B |
Dividend Yield | 0.2% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Vernova (GEV) trades at $997.09, down 3.12% today but maintains strong analyst support with 22 buy ratings and a $1,270 consensus price target. The stock shows bullish technical signals with support at $985 and resistance at $1,005. Recent Q1 2026 earnings beat expectations with $17.44 EPS, though Q2 missed. The company secured the first US construction permit for its BWRX-300 SMR, strengthening its nuclear pipeline amid growing AI-driven power demand.
Outlook remains positive with 2026 revenue projected at $41.4B and net profit margin expanding to 23.03%. Key risks include valuation concerns with P/E of 28.65 and execution challenges in the wind segment. The stock offers 27% upside to consensus target, supported by strong institutional sentiment and AI infrastructure tailwinds.
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
